Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT)

Exclusion Criteria

• •Prior treatment for subfoveal choroidal neovascularization (CNV).
• •Prior treatment for juxtafoveal or extrafoveal CNV involving previous antiangiogenic agent, photodynamic therapy, or intravitreal triamcinolone acetate.
• •History of vitrectomy or submacular surgery in the study eye.
• •Subretinal fibrosis accounting for more than 50% of the lesion.
• •Non-CNV lesion components account for more than 50% of the total lesion components.
• •CNV due to causes other than AMD.
• •Retinal pigmented epithelial tear involving the center of the macula.
• •Geographic atrophy involving the central macula.
• •Any concurrent intraocular condition in the study eye that in the opinion of the investigator could require surgical or medical intervention during the course of the study (i.e. cataract).
• •Active intraocular inflammation.
• •Vitreous hemorrhage in the eye.
• •History of spherical equivalent in the study eye greater than negative 8 diopters.
• •Intraocular surgery within 2 months of study enrollment.
• •Uncontrolled glaucoma in the study eye. Defined as intraocular pressure greater than 30mmHg despite treatment with anti-glaucoma medication.
• •History of other disease, such as recent myocardial infarction, recent cerebral vascular accident, or uncontrolled hypertension that in the opinion of the investigator might render the subject at high risk for complication.
• •Inability to comply with study or follow-up procedures.